Management of moderate to severe Alzheimer's disease: Focus on memantine

Taiwanese Journal of Obstetrics and Gynecology

Volumn 50, Issue 4, 2011, Pages 415-423

  Dominguez, Evangelyn ^a   Chin, Ting Yu ^a   Chen, Chih Ping ^b,c,d,e   Wu, Tzong Yuan ^a  

^a CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Alzheimer's disease; Excitotoxicity; IRES; Memantine; NMDA receptors

Indexed keywords

CHOLINESTERASE INHIBITOR; DIZOCILPINE; DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERAMEXANE; PLACEBO; RIVASTIGMINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; ANXIETY DISORDER; CHRONIC PAIN; CONCENTRATION RESPONSE; DEPRESSION; DISEASE SEVERITY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DEPENDENCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; GLAUCOMA; HEPATIC ENCEPHALOPATHY; HUMAN; IC 50; MONOTHERAPY; MULTIPLE SCLEROSIS; NAUSEA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; RECOMMENDED DRUG DOSE; REVIEW; TARDIVE DYSKINESIA; TINNITUS; VOMITING;

ALZHEIMER DISEASE; DOPAMINE AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84855251927     PISSN: 10284559     EISSN: 18756263     Source Type: Journal    
DOI: 10.1016/j.tjog.2011.10.004     Document Type: Review

References (32)

1. Lipton S.A. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2005, 2:155-165.
2. Dementia in the Asia Pacific region: the epidemic is here [pdf] 2006, Access Economics PTY Limited (a report for Asia Pacific Members of Alzheimer's Disease International), Access Economics, Australia, Available atAccessed July 14 2010. http://www.alz.co.uk/research/asiapacificreport.html.
3. Alz.org: What is Alzheimer's: http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp.
4. Doody R., Wirth Y., Schmitt F., Möbius H.-J. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord 2004, 18:227-232.
5. Savioz A., Leuba G., Vallet P.G., Walzer C. Contribution of neural networks to Alzheimer disease's progression. Brain Res Bull 2009, 80:309-314.
6. Bonda D.J., Lee H.-P., Lee H.-G., Friedlich A.L., Perry G., Zhu X., et al. Novel therapeutics for Alzheimer's disease: an update. Curr Opin Drug Discovery Devel 2010, 13(2):235-246.
7. Wu T.-Y., Chen C.-P. Dual action of memantine in Alzheimer disease: a hypothesis. Taiwan J Obstet Gynecol 2009, 48(3):273-277.
8. de Felice F.G., Velasco P.T., Lambert M.P., Viola Kirsten, Fernandez Sara J., Ferreira Sergio T., et al. Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 2007, 282(15):11590-11601.
9. Lipton S.A. Turning down, but not off. Neuroprotection requires a paradigm shift in drug development. Nature 2004, 428:473.
10. Beal M.F. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000, 23:298-304.
11. Danysz W., Parsons C.G. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 2003, 18:S23-S32.
12. Danysz W., Parsons C.G., Möbius H.-J., Stöffler A., Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease-a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 1999, 2:85-97.
13. Chen H.-S., Pellegrini J.W., Aggarwal S.K., Lei Sizheng Z., Warach Steven, Jensen Frances E., et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated toxicity. J Neurosci 1992, 12(11):4427-4436.
14. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well-tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacol 1999, 38:735-767.
15. Blanpied T.A., Boeckman F.A., Aizenman E., Johnson J.W. Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol 1997, 77:309-323.
16. Parsons C.G., Panchenko V.A., Pinchenko V.O., Tsyndrenko A.Y., Krishtal O.A. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 1996, 8:446-454.
17. Rogawski M.A., Wenk G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Reviews 2003, 9(3):275-308.
18. van Dyck C.H., Schmitt F.A., Olin J.T. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry 2006, 14(5):428-437.
19. Johnson J.W., Kotermanski S.E. Mechanism of action of memantine. Curr Opin Pharmacol 2006, 6:61-67.
20. high receptors. Synapse 2008, 62:149-153.
21. Parsons C., Stoffler A., Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacol 2007, 53:699-723.
22. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial. JAMA 2004, 291(3):317-324.
23. Dantoine T., Auriacombe S., Sarazin M., Becker H., Pere J.-J., Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 2006, 60(1):110-118.
24. Gauthier S., Wirth Y., Möbius H.J. Effects of memantine on behavioral symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 2005, 20:459-464.
25. Nakamura S., Murayama N., Noshita T., Katsuragi R., Ohno T. Cognitive dysfunction induced by sequential injection of amyloid-β and ibotenate into the bilateral hippocampus; protection by memantine and MK-801. Euro J Pharmacol 2006, 548:115-122.
26. Wenk G.L., Danysz W., Mobley S.L. Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Res 1994, 655:7-11.
27. Wenk G.L., Danysz W., Mobley S.L. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol Environ Toxicol 1995, 293:267-270.
28. Wenk G.L., Zajaczkowski W., Danysz W. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin. Behav Brain Res 1997, 83:129-133.
29. Zajaczkowski W., Frankiewicz T., Parsons C.G., Danysz W. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacol 1997, 36:961-971.
30. Yamada K., Takayanagi M., Kamei H., Nagai T., Dohniwa M., Kobayashi K., et al. Effects of memantine and donepezil on amyloid β-induced memory impairment in a delayed-matching to position task in rats. Behav Brain Res 2005, 162:191-199.
31. Minkeviciene R., Banerjee P., Tanila H. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2004, 311(2):677-682.
32. Zoladz P.R., Campbell A.M., Park C.R., Schaefer D., Danysz W., Diamond D.M. Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacol, Biochem and Behav 2006, 85:298-306.